Find uplifting stories about heroes, innovations, and solutions
64 results for "semaglutide"
Millions who avoid needles can now access a breakthrough weight loss medication in pill form. The FDA just approved oral semaglutide and a higher-dose option, making effective obesity treatment easier than ever.
A breakthrough study of 95,000 patients found that semaglutide, the active ingredient in Ozempic and Wegovy, significantly reduces the risk of worsening mental health in people with diabetes and depression. The discovery could offer hope for millions living with both conditions.
A major new study brings surprising good news for people taking the diabetes medication semaglutide (Ozempic). Despite losing more weight than users of other medications, they experienced 15% fewer bone fractures.
A diabetes medication known for weight loss is proving to be a powerful ally for kidney and heart health. New research shows semaglutide can slow kidney disease progression and save lives.
Semaglutide, the active ingredient in Ozempic and Wegovy, helped people with obesity reduce heavy drinking days by 41% in a groundbreaking six-month trial. This marks the first randomized study testing GLP-1 drugs for alcohol use disorder treatment.
A groundbreaking study shows that semaglutide, the medication in Wegovy and Ozempic, extended the lifespan of older mice by 12 percent while boosting memory and physical health. Scientists believe they may have found a drug that delivers the longevity benefits of calorie restriction without the hunger.
A daily pill form of semaglutide (the drug in Ozempic) helped people with alcohol use disorder drink less heavily in a University of Colorado trial. The breakthrough suggests these medications could offer new hope for treating addiction beyond their current uses.
More people with obesity are getting treatment now than at any point in the past 20 years, thanks to breakthrough medications like semaglutide. A major study tracking over 200,000 patients shows how policy changes and new drugs transformed access to life-changing care.
Brazil just approved a new semaglutide treatment that could help 16.5 million people with diabetes access life-changing medication. The affordable option launches later this year, with the potential to reach millions who currently go undiagnosed or untreated.
Scientists discovered that semaglutide, the drug behind Ozempic and Wegovy, can rebuild damaged cartilage in people with arthritis even without weight loss. The breakthrough hints at a powerful new treatment for millions suffering from joint pain.
Semaglutide, the medication in Ozempic and Wegovy, reduced psychiatric hospital visits by 21% for people with bipolar disorder in a study of 15,000 patients. Scientists believe the drug may help stabilize mood by reducing brain inflammation.
A diabetes drug already transforming weight loss may offer unexpected hope for millions living with bipolar disorder. Swedish research reveals people taking semaglutide faced significantly fewer psychiatric crises.
A groundbreaking trial found that semaglutide, the popular weight loss drug, significantly reduced alcohol cravings and heavy drinking days in people battling both obesity and alcohol addiction. The discovery could transform treatment options for millions worldwide struggling with alcohol use disorder.
Scientists discovered that semaglutide, a popular diabetes and weight loss medication, extended the lives of older female mice by 12% and slowed multiple signs of aging. The drug may work by mimicking the benefits of calorie restriction without requiring people to drastically reduce their food intake.
A breakthrough study shows the diabetes drug semaglutide helps older adults lose significant weight safely while improving heart health. Nearly half of participants over 65 achieved at least 15% weight loss in just over a year.
The diabetes and weight-loss medication semaglutide (Ozempic/Wegovy) just proved effective at treating alcohol-use disorder in a major clinical trial. Millions struggling with problem drinking now have a new treatment option their doctors already know how to prescribe.
Weight loss drug semaglutide shows unexpected mental health benefits in 100,000-person study. Depression, anxiety, and addiction rates plummeted during treatment periods.
A clinical trial shows semaglutide, the drug in Ozempic and Wegovy, slowed biological aging markers by 9% in just 32 weeks. Scientists say it's the first randomized evidence that a widely available medication may slow cellular aging processes.
Scientists discovered that semaglutide, the drug in Ozempic and Wegovy, helped older mice live longer and stay healthier. The findings suggest GLP-1 drugs might influence the aging process itself, not just appetite and blood sugar.
The Department of Veterans Affairs is launching a major study to see if semaglutide, the ingredient in Ozempic and Wegovy, can help veterans overcome alcohol addiction. Early research suggests the diabetes and weight-loss drug may reduce cravings and drinking just like it quiets "food noise" for people with obesity.
Showing 20 of 64